1. Home
  2. HYPR vs CTSO Comparison

HYPR vs CTSO Comparison

Compare HYPR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

HOLD

Current Price

$1.08

Market Cap

104.0M

Sector

Health Care

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.73

Market Cap

49.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYPR
CTSO
Founded
2014
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.0M
49.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HYPR
CTSO
Price
$1.08
$0.73
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$1.28
$5.38
AVG Volume (30 Days)
625.1K
126.1K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,591,000.00
$36,979,520.00
Revenue This Year
$5.17
$9.51
Revenue Next Year
$35.44
$24.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.89
52 Week Low
$0.53
$0.60
52 Week High
$2.22
$1.61

Technical Indicators

Market Signals
Indicator
HYPR
CTSO
Relative Strength Index (RSI) 48.74 46.64
Support Level $0.85 $0.70
Resistance Level $1.18 $0.85
Average True Range (ATR) 0.09 0.07
MACD 0.01 0.01
Stochastic Oscillator 68.37 52.04

Price Performance

Historical Comparison
HYPR
CTSO

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: